Pirprofen

Pirprofen Struktur
31793-07-4
CAS-Nr.
31793-07-4
Bezeichnung:
Pirprofen
Englisch Name:
Pirprofen
Synonyma:
Su-21524;Pirprofen;Pirprofen USP/EP/BP;PIDSZXPFGCURGN-UHFFFAOYSA-N;3-Chloro-4-(3-pyrrolin-1-yl)hydratropic acid;2-[3-Chloro-4-(3-pyrrolin-1-yl)phenyl]propanoic acid;2-(3-Chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl)propanoic acid;2-[3-Chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl]propionic acid;2-[3-Chloro-4-(2,5-dihydro-1H-pyrrole-1-yl)phenyl]propanoic acid;Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-α-methyl-
CBNumber:
CB2875239
Summenformel:
C13H14ClNO2
Molgewicht:
251.71
MOL-Datei:
31793-07-4.mol

Pirprofen Eigenschaften

Schmelzpunkt:
98-100°
Siedepunkt:
410.8±45.0 °C(Predicted)
Dichte
1.1778 (rough estimate)
Brechungsindex
1.5270 (estimate)
storage temp. 
-20°C Freezer, Under inert atmosphere
Löslichkeit
DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
4.56±0.10(Predicted)
Farbe
Off-White

Sicherheit

Pirprofen Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Pirprofen is a non-steroidal anti-inflammatory drug.

Weltgesundheitsorganisation (WHO)

Pirprofen, a nonsteroidal anti-inflammatory agent, was introduced in 1982 primarily for the treatment of rheumatic diseases, as well as for use in posttraumatic and post-operative inflammatory conditions, acute gout and dysmenorrhoea. Reports of serious adverse effects, in particular cases of liver toxicity, some of which were fatal, led the manufacturer, in 1985 and in 1989, to amend the approved product information of the drug, limiting duration of treatment and lowering the recommended doses. In the light of these successive restrictions, which have considerably reduced the field of application of pirprofen and in view of available alternatives, the manufacturer has decided to discontinue the drug worldwide.

Synthese

Synthesis: treatment of the sodium salt of diethyl methylmalonate with 2,4- dichloronitrobenzene yields diethyl (3-chloro- 4-nitrophenyl)methylmalonate. Saponification, decarboxylation, and subsequent reesterification followed by catalytic reduction gives ethyl 4-amino-3-chloro-α-methylbenzeneacetate hydrochloride. Treatment of the latter with 1,4- dichloro-2-butene in the presence of sodium carbonate followed by saponification affords pirprofen.
Pirprofen synthesisPirprofen synthesis

Pirprofen Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Pirprofen Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 16)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 22787 58
Aladdin Scientific
+1-+1(833)-552-7181
sales@aladdinsci.com United States 57505 58
TargetMol Chemicals Inc.
+8613564774135
zijue.cai@tsbiochem.com United States 19884 58
Shanghai Haohong Pharmaceutical Co., Ltd. 4008210725 4008210725
malulu@leyan.com China 54987 58
Wuhan pengyin Pharmaceutical Co., Ltd 13163333255
1939328613@qq.com China 395 58
Energy Chemical 021-58432009 400-005-6266
marketing@energy-chemical.com China 44918 58
TargetMol Chemicals Inc. 4008200310
marketing@tsbiochem.com China 24644 58
Shaanxi kelkai Pharmaceutical Technology Co., Ltd 029-029-2148545164 17392779578
2148545164@qq.com China 4869 58
Baoji Didu Pharmaceutical and Chemical Co., Ltd 02961856358 15829046862
1035@dideu.com China 10011 58
Shanghai Aladdin Biochemical Technology Co.,Ltd. +86-18521732826
market@aladdin-e.com China 48461 58

31793-07-4(Pirprofen)Verwandte Suche:


  • Pirprofen
  • 2-[3-Chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl]propionic acid
  • 2-[3-Chloro-4-(2,5-dihydro-1H-pyrrole-1-yl)phenyl]propanoic acid
  • 2-[3-Chloro-4-(3-pyrrolin-1-yl)phenyl]propanoic acid
  • 3-Chloro-4-(3-pyrrolin-1-yl)hydratropic acid
  • Su-21524
  • PIDSZXPFGCURGN-UHFFFAOYSA-N
  • Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-α-methyl-
  • Pirprofen USP/EP/BP
  • 2-(3-Chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl)propanoic acid
  • 31793-07-4
Copyright 2019 © ChemicalBook. All rights reserved